Medication Safety in Intravenous Therapy: Compatibility of Etoposide With Frequently Drugs Used in Tumour Critical Care During Simulated Y-Site Administration [Corrigendum]
Ding H, Tong T, Liu S, Tang L, Chen Z. Drug Des Devel Ther. 2025;19:1147—1161. The authors have advised there is an error in Figure 1 on page 1151. The text “Particles > 25 µm≤25 particles/mL” should read “Partic...
Saved in:
| Main Authors: | Ding H, Tong T, Liu S, Tang L, Chen Z |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-03-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/corrigendum-medication-safety-in-intravenous-therapy-compatibility-of--peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hypersensitivity reaction to etoposide. A case report
by: M. Mullera Martí, et al.
Published: (2014-05-01) -
Cytotoxic Effect of Escitalopram/Etoposide Combination on Etoposide-Resistant Lung Cancer
by: Serap Özkaya Gül, et al.
Published: (2025-04-01) -
Compatibility and Stability of Cipepofol (Ciprofol) and Etomidate Mixture for Intravenous Anesthesia
by: Linzhong Zhang, MD, et al.
Published: (2025-01-01) -
Evaluation of the Efficacy of Intravenous Push and Intravenous Piggyback Ceftriaxone in Critically Ill Patients
by: Elly R. Sherman, et al.
Published: (2024-09-01) -
ADENOVIRUS TYPE 5 REACTIVATION IN T- LYMPHOBLAST HUMAN CELL AFTER ETOPOSIDE TREATMENT
by: Zeenah Weheed Atwan
Published: (2020-04-01)